NCT01069510
Spironolactone in Adult Congenital Heart Disease
See it on ClinicalTrials.gov ↗15 people
40%
60%
6 womenmiddle line = equal numbers9 men
- Phase
- PHASE2
- Paid for by
- Oregon Health and Science University
- Finished
- 2017-03
- Health conditions
- Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
- Who could join
- Anyone
- Ages
- 18 Years – 80 Years
- Average age
- mean 37 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Positive urine pregnancy test.”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Renal insufficiency (estimated creatinine clearance \< 30 ml/min/1.73m2),”
Study titles and rules are shown in their original English.